Pfizer is continuing to develop a once-daily version of its experimental weight loss pill danuglipron after seeing encouraging data from an early-stage trial testing multiple doses. The company plans to conduct more early-stage studies in the second half of 2024 to identify the optimal dose of the once-daily pill, with results expected in Q1 2025. Pfizer discontinued a twice-daily version of the drug after patients had trouble tolerating it in a mid-stage trial in late 2023. Danuglipron works similarly to approved GLP-1 drugs like Wegovy by mimicking the GLP-1 hormone to signal fullness to the brain.